Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyperpolarized xenon Xe 129 is an inhaled diagnostic imaging agent used in conjunction with magnetic resonance imaging (MRI) and spectroscopy to evaluate pulmonary function. The agent consists of the stable isotope xenon-129, which is hyperpolarized—typically via spin-exchange optical pumping—to significantly enhance its nuclear magnetic resonance signal. This technology allows for the non-invasive, three-dimensional visualization of lung ventilation and the quantification of gas exchange across the alveolar-capillary barrier. Specifically, it measures the transfer of the gas from the airspaces into the lung tissue (barrier) and subsequently into the red blood cells. At Duke University, this imaging modality is being investigated under an Investigational New Drug (IND) application to assess disease severity, functional impairment, and treatment response in patients with idiopathic pulmonary fibrosis (IPF).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xenon Xe 129 hyperpolarized.